MannKind Reports Strong Q4 Revenue Growth, Highlights Key FDA Decisions for Afrezza and Furoscix in 2026

summarizeSummary

MannKind Corporation reported strong Q4 and full-year 2025 revenue growth, driven by Afrezza and Furoscix sales, and highlighted a catalyst-rich 2026 with two upcoming FDA decisions for key products.

check_boxKey Events

• Strong Q4 and Full Year 2025 Revenue Growth

  MannKind reported Q4 2025 revenues of $112 million, a 46% increase year-over-year, and full-year 2025 revenues of $349 million, up 22% from 2024. This growth was primarily driven by Furoscix net sales of $23 million (following its acquisition on October 7, 2025) and Afrezza net sales of $23 million, a 25% increase.

• Two Key FDA Decisions Expected in 2026

  The company announced two significant PDUFA target action dates: May 29, 2026, for the supplemental Biologics License Application (sBLA) for Afrezza in pediatrics, and July 26, 2026, for the supplemental New Drug Application (sNDA) for the Furoscix ReadyFlow Autoinjector.

• Strategic Product and Pipeline Advancements

  Recent positive developments include the FDA's Q1 2026 approval of an updated Afrezza label with starting dose guidance, the ADA's 2026 Standards of Care recommending inhaled insulin, and the launch of Afrezza in India. Pipeline progress includes enrollment in the Phase 1b study for Nintedanib DPI (MNKD-201) with topline data expected in 2H 2026, and initiation of a Phase 2 clinical trial.

• Shift to Net Loss in Q4 2025

  Despite strong revenue growth, MannKind reported a net loss of $(15.9) million in Q4 2025, compared to a net income of $7.4 million in Q4 2024. Full-year net income also decreased significantly to $5.9 million from $27.6 million in 2024, primarily due to increased R&D and SG&A expenses related to growth initiatives and the scPharma acquisition.

auto_awesomeAnalysis

This 8-K details MannKind's Q4 and full-year 2025 financial results, showcasing robust revenue growth for its commercial products, particularly Afrezza and the newly acquired Furoscix. While the company reported a net loss in Q4 2025, this appears to be influenced by increased R&D and SG&A expenses related to pipeline advancement and the integration of Furoscix. The most significant market-moving information for a life sciences company like MannKind is the announcement of two near-term PDUFA dates: May 29, 2026, for Afrezza's pediatric indication and July 26, 2026, for the Furoscix ReadyFlow Autoinjector. These regulatory milestones, coupled with positive developments like the ADA's recommendation for inhaled insulin and pipeline progress, position MannKind for potential significant growth catalysts in 2026. Investors should monitor the outcomes of these FDA decisions closely.